Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: During bosentan treatment, progressive improvement of exercise capacity was observed. Walk distance increased in seven patients, remained unchanged in three and slightly decreased in three patients. A progressive significant decrease of right ventricular systolic pressure was also observed, whereas pulmonary artery mean pressure remained unchanged. Adverse effects related to bosentan (elevation of hepatic aminotransferases) were noted in two patients. CONCLUSION:
|
Authors | F Cozzi, R Montisci, H Marotta, F Bobbo, N Durigon, M Ruscazio, P Sfriso, S Iliceto, S Todesco |
Journal | European journal of clinical investigation
(Eur J Clin Invest)
Vol. 36 Suppl 3
Pg. 49-53
(Sep 2006)
ISSN: 0014-2972 [Print] England |
PMID | 16919011
(Publication Type: Journal Article)
|
Chemical References |
- Antihypertensive Agents
- Sulfonamides
- Bosentan
|
Topics |
- Administration, Oral
- Adult
- Aged
- Antihypertensive Agents
(administration & dosage)
- Blood Pressure
(physiology)
- Bosentan
- Connective Tissue Diseases
(complications, physiopathology)
- Exercise Test
(methods)
- Female
- Humans
- Hypertension, Pulmonary
(drug therapy, etiology, physiopathology)
- Lupus Erythematosus, Systemic
(complications, physiopathology)
- Male
- Middle Aged
- Mixed Connective Tissue Disease
(complications, physiopathology)
- Myositis
(complications, physiopathology)
- Prospective Studies
- Scleroderma, Systemic
(complications, physiopathology)
- Sulfonamides
(administration & dosage)
- Treatment Outcome
- Ventricular Dysfunction, Right
(physiopathology)
- Walking
(physiology)
|